Fleet Bioprocessing Ltd

on . Posted in SME

FleetFleet Bioprocessing Ltd. is a UK-based contract development and manufacturing company, specializing in clinical diagnostic tests such as immunoassays. Within the project Fleet is responsible for the development of enzyme-based immunoassays (ELISAs) for a range of biomarkers defined in Work Package 1. These biomarkers are defined primarily by having shown promising correlations with cardiovascular risk in transcriptomic studies.

Once these ELISAs have been developed, Fleet is also responsible for the manufacture of reagents to allow them to be used by Universitätsklinikum Hamburg-Eppendorf, UKE to test samples provided by other project partners. Initially, this comprises testing of a case cohort of ~11K samples, and if the relevant biomarker shows promise in this study with respect to cardiovascular risk prediction, the ELISA may be used on a wider panel of samples.

Fleet and UKE also cooperate on a transfer process to ensure that the ELISAs can be used effectively at UKE to generate reliable results.

ELISA technology is a well-established technique whereby the specificity of antibodies is exploited to immobilize molecules of interest from a sample, and to detect them by means of a colour change which is quantitatively related to the concentration of that molecule in the sample. Within this project, all the biomarkers of interest are proteins whose high molecular weight allow them to be detected using an immunometric or sandwich ELISA design:


Fleet's ELISAs employ the enzyme horseradish peroxidase (HRP) and its chromogenic substrate 3,3',5,5'-tetramethylbenzidine (TMB) to provide a sensitive colour change.

Colorimetric ELISAs are readily transferable between test sites, requiring only simple, commonly-encountered equipment for their execution. Being based on 96-well microtitre plates, they are also amenable to testing large numbers of samples, as required in this project.